Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 4Gastrointestinal 4Thoracic 3Gynecologic 2Genitourinary 2Dermatologic 2Other solid neoplasm 1Breast 1

Conditions

Carcinoma, Renal Cell 9Prostatic Neoplasms 8Urinary Bladder Neoplasms 7Melanoma 7Neoplasms 5Head and Neck Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 3Carcinoma, Merkel Cell 3Squamous Cell Carcinoma of Head and Neck 2Kidney Neoplasms 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Uterine Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1Recurrence 1Penile Neoplasms 1Mesothelioma, Malignant 1Lymphoma, Non-Hodgkin 1

Interventions

pembrolizumab 23Nivolumab 20atezolizumab 10Specimen Handling 8Ipilimumab 8Cyclophosphamide 8cabozantinib 6Magnetic Resonance Spectroscopy 6fludarabine 5Sorafenib 5sargramostim 4Trastuzumab 4Sunitinib 4Bevacizumab 4lenvatinib 3enzalutamide 3durvalumab 3avelumab 3X-Rays 3Paclitaxel 3Fluorodeoxyglucose F18 3Docetaxel 3Albumin-Bound Paclitaxel 3ulixertinib 2spartalizumab 2relatlimab 2regorafenib 2palbociclib 2epacadostat 2cemiplimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × cemiplimab × Genitourinary × Clear all
NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

University of Pittsburgh

Phase 3 Completed
161 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡